Sanjeet S. Grewal, M.D.

Evaluate the feasibility and safety of AMSCs for adults with medically refractory epilepsy who are undergoing bilateral lead implantation for DBS. Single dose of 10µl [5x106 cells/ml], intraparenchymal stereotactic delivery.

The mechanisms behind how we experience the world, form memories, and make future decisions is poorly understood. We perform an observational study of rare epilepsy patients implanted with electrocorticrographic (ECoG) and stereoencephalographic (sEEG) devices in our epilepsy monitor unit to record brain signals during cognitive and memory tasks. The neural signals recorded during these computerized tasks will be invaluable for not only to discover the mysteries of our cognition, but to also advance the next generation of future diagnostic or therapeutic strategies in countless neurological diseases that affect human cognition.

The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation (DBS) of the dentate nucleus area for improving functional status in patients with moderate to severe residual upper-extremity motor impairment due to stroke.

This is a study of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE). It is designed to investigate the Safety, Tolerability, and Efficacy of AMT-260 in Adults with MTLE Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED).

The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation (DBS) of the dentate nucleus area for improving functional status in patients with moderate to severe residual upper-extremity motor impairment due to stroke.

The purpose of this study is to demonstrate that the RNS® System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.